Evidence map›Paper›PMID 41576959›Full record

ArticleImmunity2026

Innate lymphoid cells activated by the cytokine TL1A link colitis to emergency granulopoiesis and the recruitment of tumor-promoting neutrophils.

Sílvia Pires, Wei Yang, Sofia Frigerio, Cynthia Louis, Chloe Scott, Yu Lin Zhou, Emre Cardakli, Nancy Tran, Mina Hassan-Zahraee, Zhan Ye and 14 more

Abstract read
In one paragraph

Article in Immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sílvia PiresJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. Electronic address: sdp4001@med.cornell.edu.
Wei YangJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Sofia FrigerioDepartment of Gastroenterology and Hepatology & Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
Cynthia LouisWalter and Eliza Hall Institute of Medical Research and Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
Chloe ScottJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Yu Lin ZhouJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Emre CardakliJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Nancy TranJill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.
Mina Hassan-ZahraeePfizer Inc., Cambridge, MA, USA.
Zhan YePfizer Inc., Cambridge, MA, USA.
Craig HydePfizer Inc., Cambridge, MA, USA.
Kenneth HungPfizer Inc., Cambridge, MA, USA.
Amanda ChenImmunology Program of the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Charles NgDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Alexander GrierJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
JRI Live Cell BankJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Dana LukinJill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.
Ellen ScherlJill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.
Stephan R TarganF. Widjaja Foundation Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Gretchen E DiehlImmunology Program of the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joep GrootjansDepartment of Gastroenterology and Hepatology & Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
Tracy L PutoczkiWalter and Eliza Hall Institute of Medical Research and Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
Ian WicksWalter and Eliza Hall Institute of Medical Research and Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
Randy S LongmanJill Roberts Institute for Research in Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA; Jill Roberts Center for Inflammatory Bowel Disease, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA. Electronic address: ral2006@med.cornell.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Orchestrating intestinal immunity through microbiota-CX3CR1+ cell interactions R01AI125264 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI GRETCHEN E DIEHL · 2017 to 2026
$4.1M
TL1A Regulation of Group 3 Innate Lymphoid Cells in ColitisR01DK120985 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI Randy S Longman · 2020 to 2026
$2.9M
A randomized, placebo-controlled clinical trial examining the efficacy of Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in patients with moderate ulcerative colitis (MINDFUL)R01DK128257 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI LONGMAN, RANDY S · 2021 to 2023
$1.0M
Investigating the Role of the Microbiome in Mononuclear Phagocyte FunctionF31AI181447 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Amanda Chen · 2024 to 2026
$149k
NCI NIH HHS P30 CA008748NIAID NIH HHS F31 AI181447NIAID NIH HHS R01 AI125264NIDDK NIH HHS R01 DK120985NIDDK NIH HHS R01 DK128257
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC). Genetic variants in TNFSF15, encoding tumor necrosis factor (TNF)-like cytokine 1A (TL1A), associate with severe IBD and advanced CRC. Here, we investigated how TL1A signaling promotes colitis-associated tumorigenesis. Deletion of the TL1A receptor in tissue-resident type 3 innate lymphoid cells (ILC3s) reduced colitis-associated tumorigenesis. TL1A signaling promoted neutrophil recruitment to the colon, which was required for tumor development. TL1A-stimulated ILC3s activated neutrophils, inducing a tumor-associated neutrophil (TAN)-like gene signature, and transfer of these neutrophils was sufficient to promote tumor growth. A similar TAN-like gene signature was enriched in human colitis-associated dysplasia but reduced following TL1A blockade in ulcerative colitis patients. Mechanistically, TL1A and colitis triggered emergency granulopoiesis, expanding granulocyte-monocyte progenitors and neutrophils in a manner dependent on ILC3-derived granulocyte-macrophage colony-stimulating factor (GM-CSF). Thus, a TL1A-ILC3-GM-CSF axis links colitis with emergency granulopoiesis and may serve as a therapeutic target to reduce colitis-associated CRC.

Indexed as

ColitisColorectal NeoplasmsGranulocytesLymphocytesNeutrophilsTumor Necrosis Factor Ligand Superfamily Member 15AnimalsGranulocyte-Macrophage Colony-Stimulating FactorHumansImmunity, InnateMiceMice, Inbred C57BLMice, KnockoutNeutrophil InfiltrationSignal TransductionGranulocyte-Macrophage Colony-Stimulating FactorTNFSF15 protein, humanTnfsf15 protein, mouseTumor Necrosis Factor Ligand Superfamily Member 15colitis-associated canceremergency granulopoiesisGM-CSFIBDinnate lymphoid cellsneutrophilsTL1A

Identifiers

PMID41576959
PMCPMC12981380

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.